Compare ATHM & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATHM | PHVS |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2013 | 2020 |
| Metric | ATHM | PHVS |
|---|---|---|
| Price | $21.97 | $36.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $28.00 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 710.1K | 461.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 9.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.77 | N/A |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.57 | $20.65 |
| 52 Week High | $29.92 | $36.93 |
| Indicator | ATHM | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 55.34 |
| Support Level | $21.98 | $24.73 |
| Resistance Level | $22.24 | $36.07 |
| Average True Range (ATR) | 0.61 | 1.90 |
| MACD | -0.22 | 0.12 |
| Stochastic Oscillator | 33.54 | 71.86 |
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent, and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead-generation service provider in China's online auto platform media advertising market, in terms of media services and lead-generation revenue.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.